Parkinson’s disease treatment questioned

Associated Press

WASHINGTON — A protein that exists normally in most of the cells in the brain has been identified as a possible factor in the development of Parkinson’s disease — a finding that could point the way to treatments but raise questions about current therapy.

In lab experiments, when the brain protein alpha-synuclein combines with dopamine in nerve cells it can trigger the production of toxic reactive oxygen molecules that kill the nerves, reports a research team led by Dr. Bruce Yankner of Harvard Medical School.

If this process operates in patients the same way it does in the laboratory, it could set scientists on the path to potential treatments, Yankner said.

But it also adds to the debate over whether the current use of dopamine in the treatment of Parkinson’s could make things worse in the long run, he added.

The findings appear in the June issue of the journal Nature Medicine.

Dr. Ronald Lee Hamilton of the University of Pittsburgh called the research "a significant advance, but not a major breakthrough."

"It does not address the question of why alpha-synuclein accumulates in these neurons, but it does provide a potential mechanism by which these neurons might die," he said.

Dr. Robert Burke of Columbia University said the study "adds to the growing body of information which is pointing toward the importance of synuclein’s role in affecting the viability of dopamine neurons."

Neither Hamilton nor Burke was connected with the research team.

More than a million Americans are victims of Parkinson’s, which causes muscle stiffness and tremor as neurons in the brain are damaged.